Welcome
Support Centre
03 September 2014 
ISRCTN Register - International Standard Randomized Controlled Trial Number
Trial registration
Unique identification scheme
International databases
home  |   my details  |   ISRCTN Register  |   mRCT  |   links  |   information  |   news
Find trials
ISRCTN Register
tips on searching

Registration
New application
Updating record

Information
introduction
governing board
ISRCTN FAQs
data set
letter of agreement
request information
guidance notes
statistics

[ Print-friendly version ]
Prospective study on the effects of adalimumab treatment in patients with rheumatoid arthritis
ISRCTN ISRCTN68762628
DOI 10.1186/ISRCTN68762628
ClinicalTrials.gov identifier
EudraCT number
Public title Prospective study on the effects of adalimumab treatment in patients with rheumatoid arthritis
Scientific title
Acronym adalimumab
Serial number at source N/A
Study hypothesis To evaluate the response to adalimumab treatment in Tumour Necrotising Factor (TNF)-alpha blockade naÏve patients and patients who failed prior other anti-TNF-alpha treatment and to understand the mechanisms underlying the clinical response to TNF-alpha blockade.
Lay summary
Ethics approval Approval received from the Medical ethical committee of the Academic Medical Center/University of Amsterdam on the 12th February 2004 (ref: MEC04/007).
Study design Single-centre open label prospective, exploratory phase IV study
Countries of recruitment Netherlands
Disease/condition/study domain Rheumatoid arthritis
Participants - inclusion criteria 1. Patients with the diagnosis rheumatoid arthritis according to the American Rheumatism Association (ARA) 1987 criteria and in American College of Rheumatology (ACR) 1991 functional classes I, II, and III
2. The patient is naÏve for anti-TNF-alpha therapy or has failed other prior TNF-alpha blockers
3. Disease Activity Score (DAS 28) more than or equal to 3.2
4. Age 18 to 85 years old
5. Use concurrent methotrexate treatment (5 - 30 mg/week stable since at least 28 days before initiation) during the study. Subjects may be taking nonsteroidal anti-
inflammatory drugs, provided the dose and frequency have been stable for at least 28 days. Subjects may be receiving prednisone therapy less than or equal to 10 mg/day rovided that the dosage has been stable for at least two months prior to entry
Participants - exclusion criteria 1. Pregnancy
2. Breastfeeding
3. A history of or current acute inflammatory joint disease of different origin e.g. mixed connective tissue disease, seronegative spondylarthropathy, psoriatic arthritis, Reiter's syndrome, systemic lupus erythematosus or any arthritis with onset prior to age 16 years
4. Acute major trauma
5. Therapy within the previous 60 days with:
a. any experimental drug
b. alkylating agents
c. antimetabolites
d. monoclonal antibodies (including infliximab and etanercept)
e. growth factors
f. other cytokines
6. Therapy within the previous 28 days with:
a. parenteral or intra-articular corticoid injections
b. oral corticosteroid therapy exceeding a prednisone equivalent of 10 mg daily
c. present use of Disease Modifying Anti-Rheumatic Drugs (DMARDs) other than methotrexate
7. Receipt of any live (attenuated) vaccines within four weeks prior to baseline
8. Fever (orally measured more than 38°C), chronic infections or infections requiring anti-microbial therapy
9. Known positive reaction to hepatitis B surface antigen or hepatitis C antigen
10. Other active medical conditions such as inflammatory bowel disease, bleeding diathesis, or severe unstable diabetes mellitus
11. Manifest cardiac failure (stage III or IV according to New York Heart Association [NYHA] classification)
12. Progressive fatal disease/terminal illness
13. A congenital or acquired (known Human Immunodeficiency Virus [HIV]-positive status) immunodeficiency
14. A history of lymphoproliferative disease or treatment with total lymphoid irradiation
15. A white cell count less than 3.5 x 10^9/l
16. Platelet count less than 100 x 10^9/l
17. Haemoglobin of less than 5.3 mmol/l
18. Body weight of less than 45 kg
19. History of drug or alcohol abuse
20. Any concomitant medical condition which would in the investigator's opinion compromise the patient's ability to tolerate, absorb, metabolise or excrete the study medication
21. Inability to give informed consent
22. Mental condition rendering the patient unable to understand the nature, scope and possible consequences of the study and/or evidence of an uncooperative attitude
Anticipated start date 07/04/2004
Anticipated end date 07/04/2005
Status of trial Completed
Patient information material
Target number of participants 50
Interventions Adalimumab 40 mg subcutaneously once every two weeks.
Primary outcome measure(s) 1. Clinical efficacy according to the EUropean League Against Rheumatism (EULAR) response criteria at week 16 after initiation of treatment
2. Exploration of clinical and serological markers that might distinguish responding from non-responding patients (e.g. the influence of anti-adalimumab antibody formation and adalimumab concentrations on response)
Secondary outcome measure(s) 1. Clinical efficacy according to the EULAR response criteria at week 40 and 52 after initiation of treatment
2. Exploration of genetic markers (e.g. cytokine polymorphisms) that are associated with clinical efficacy
3. The effects of adalimumab on bone mineral density as measured by Dual Energy X-ray Absortiometry (DEXA) scanning
4. The effects of adalimumab on lipid metabolism as measured by fasting serum lipid profiles in time
5. The effects of adalimumab on work productivity and sick leave measured by work-related questionnaires during 52 weeks follow-up
Sources of funding Academic Medical Center (AMC) (The Netherlands)
Trial website
Publications
Contact name Dr  C A  Wijbrandts
  Address Academic Medical Center (AMC)
Department of Medicine
Division of Clinical Immunology and Rheumatology, F4-218
P.O. Box 22660
  City/town Amsterdam
  Zip/Postcode 1100 DD
  Country Netherlands
  Tel +31 (0)20 566 2171
  Email c.a.wijbrandts@amc.uva.nl
Sponsor Academic Medical Center (AMC) (The Netherlands)
  Address Division of Clinical Immunology and Rheumatology
P.O. Box 22660
  City/town Amsterdam
  Zip/Postcode 1100 DD
  Country Netherlands
  Sponsor website: http://www.amc.uva.nl/#http://www.amc.uva.nl/
Date applied 22/01/2007
Last edited 26/03/2007
Date ISRCTN assigned 22/01/2007
Submit your trial protocol
Submit to Trials journal
Follow us on Twitter
© 2014 ISRCTN unless otherwise stated.